Algeta demonstrates targeted cancer-killing potential of novel alpha particle linked antibodies
Preclinical studies show 227Th-rituximab more effective at killing CD20-positive lymphoma cells than 90Y-tiuxetan-ibritumomab (Zevalin)
15-Jun-2007 -
Algeta ASA announced that a research paper showing the potential of its TH-1 technology for targeted cancer therapy has been published by "Blood", the official journal of the American Society of Hematology (ASH).
Algeta's TH-1 technology links Thorium-227, which emits alpha particles, to ...
Biogen Idec
cancer therapy
Genentech
+9